The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Eli Lilly (LLY) ended the recent trading session at $757.18, demonstrating a +0.38% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.17% ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

North Carolina is listed as a location for the manufacture of AstraZeneca and Sanofi's respiratory syncytial virus (RSV) prevention antibody, nirsevimab, as well as for GSK's two-drug HIV regimen ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...

The Trump administration acknowledges the power of business to innovate, increase productivity and help deliver broadly shared prosperity. But going all in on tariffs restrains that power by making it ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of critical drugs.

Mounjaro's launch of a weight-loss drug has sparked interest amongst the people of India despite the high price. Experts believe that making the drug locally available would help to reduce the black ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $23.00.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what ...

Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...